Predictive Oncology Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Predictive Oncology Inc. has filed its 2023 10-K report, detailing its financial performance and corporate information.</b>

AI Summary

Predictive Oncology Inc. (AGPU) filed a Annual Report (10-K) with the SEC on March 28, 2024. Predictive Oncology Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The company was formerly known as Skyline Medical Inc., Precision Therapeutic Inc., and Precision Therapeutics Inc. Predictive Oncology Inc. is incorporated in Delaware. The company's principal business address is 91 43rd Street, Suite 110, Pittsburgh, PA 15201. The SIC code for the company is 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies).

Why It Matters

For investors and stakeholders tracking Predictive Oncology Inc., this filing contains several important signals. This filing provides a comprehensive overview of the company's operations, financial health, and strategic direction for the fiscal year 2023. Investors and analysts can use this report to assess the company's performance, identify potential risks, and make informed investment decisions.

Risk Assessment

Risk Level: medium — Predictive Oncology Inc. shows moderate risk based on this filing. The company's former names and multiple name changes suggest a history of restructuring or strategic shifts, which could indicate underlying business challenges or evolving market strategies.

Analyst Insight

Review the full 10-K filing for detailed financial statements, management discussion and analysis, and risk factors to understand the company's current operational status and future outlook.

Key Numbers

• 2023-12-31 — Fiscal Year End (Report period)
• 2024-03-28 — Filing Date (Date of filing)
• 331007393 — IRS Number (Company identifier)
• 001-36790 — SEC File Number (Company identifier)

Key Players & Entities

• Predictive Oncology Inc. (company) — Filer
• Skyline Medical Inc. (company) — Former company name
• Precision Therapeutics Inc. (company) — Former company name
• Precision Therapeutic Inc. (company) — Former company name
• Pittsburgh (company) — Business address city
• DE (company) — State of incorporation
• 3842 (other) — Standard Industrial Classification
• 2023-12-31 (date) — Fiscal year end

FAQ

Key Dates

• 2023-12-31: Fiscal Year End — Defines the reporting period for the 10-K filing.
• 2024-03-28: Filing Date — Indicates when the 10-K report was officially submitted to the SEC.

Glossary

10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (This is the primary document for understanding a company's financial health and operations over the past fiscal year.)

SIC Code

Standard Industrial Classification code, a four-digit code used to classify businesses by industry. (Helps categorize the company within its specific industry sector for comparative analysis.)

Key Financial Figures

• $0.01 — ange on which registered Common stock, $0.01 par value POAI NASDAQ Capital Marke
• $4.86 — 83,374 , based upon 3,906,044 shares at $4.86 per share as reported on the NASDAQ Cap

Filing Documents

• poai20231231_10k.htm (10-K) — 1770KB
• ex_644902.htm (EX-10.9) — 64KB
• ex_644177.htm (EX-21.1) — 3KB
• ex_644827.htm (EX-23.1) — 3KB
• ex_644828.htm (EX-23.2) — 3KB
• ex_644178.htm (EX-31.1) — 12KB
• ex_644179.htm (EX-31.2) — 14KB
• ex_644180.htm (EX-32.1) — 6KB
• ex_644181.htm (EX-97) — 24KB
• 0001171843-24-001694.txt (&nbsp;) — 8580KB
• poai-20231231.xsd (EX-101.SCH) — 72KB
• poai-20231231_def.xml (EX-101.DEF) — 494KB
• poai-20231231_lab.xml (EX-101.LAB) — 442KB
• poai-20231231_pre.xml (EX-101.PRE) — 535KB
• poai-20231231_cal.xml (EX-101.CAL) — 55KB
• poai20231231_10k_htm.xml (XML) — 1365KB

BUSINESS

ITEM 1. BUSINESS 4

RISK FACTORS

ITEM 1A. RISK FACTORS 15

UNRESOLVED STAFF COMMENTS

ITEM 1B. UNRESOLVED STAFF COMMENTS 31

CYBERSECURITY

ITEM 1C. CYBERSECURITY 31

PROPERTIES

ITEM 2. PROPERTIES 32

LEGAL PROCEEDINGS

ITEM 3. LEGAL PROCEEDINGS 33

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 33 PART II

MARKET FOR REGISTRANT ' S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

ITEM 5. MARKET FOR REGISTRANT ' S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 33

[RESERVED]

ITEM 6. [RESERVED] 33

MANAGEMENT ' S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 7. MANAGEMENT ' S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 33

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 41

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 41

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 41

CONTROLS AND PROCEDURES

ITEM 9A. CONTROLS AND PROCEDURES. 41

OTHER INFORMATION

ITEM 9B. OTHER INFORMATION 42

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 42 PART III

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 43

EXECUTIVE COMPENSATION

ITEM 11. EXECUTIVE COMPENSATION 49

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 54

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 56

PRINCIPAL ACCOUNTANT FEES AND SERVICES

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 56 PART IV

EXHIBIT AND FINANCIAL STATEMENT SCHEDULES

ITEM 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES 57

FORM 10-K SUMMARY

ITEM 16. FORM 10-K SUMMARY 61

SIGNATURES

SIGNATURES 62 PART I

BUSINESS

ITEM 1. BUSINESS. General References in this annual report on Form 10-K to " Predictive " , " Company " , " we " , " us " , and " our " refer to the business of Predictive Oncology Inc. (NASDAQ: POAI) and its wholly-owned subsidiaries. Cautionary Statement Concerning Forward-Looking Statements This Annual Report on Form 10-K contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements represent our expectations and beliefs concerning future results or events, based on information available to us on the date of the filing of this Form 10-K, and are subject to various risks and uncertainties. Factors that could cause actual results or events to differ materially from those referenced in the forward-looking statements are listed in Part I, Item 1A. Risk Factors and in Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. We disclaim any intent or obligation to update or revise any of the forward-looking statements, whether in response to new information, unforeseen events, changed circumstances or otherwise, except as required by applicable law. Overview We are a knowledge and science-driven company that applies artificial intelligence ("AI") to support the discovery and development of optimal cancer therapies, which can ultimately lead to more effective treatments and improved patient outcomes. We use AI and a proprietary biobank of 150,000+ tumor samples, categorized by tumor type, to provide actionable insights about drug compounds to improve the drug discovery process and increase the probability of drug compound success. We offer a suite of solutions for oncology drug development from early discovery to clinical trials. Our mission is to change the landscape of oncology drug discovery and enable the devel

View Full Filing

View this 10-K filing on SEC EDGAR